{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:11:20Z","timestamp":1773421880882,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.atherosclerosissup.2012.10.012","type":"journal-article","created":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T17:34:24Z","timestamp":1359221664000},"page":"115-122","source":"Crossref","is-referenced-by-count":6,"title":["Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations"],"prefix":"10.1016","volume":"14","author":[{"given":"U.","family":"Schatz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Arneth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Siegels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Julius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.R.","family":"Bornstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.atherosclerosissup.2012.10.012_bib1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1744-9987.2009.00715.x","article-title":"Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients","volume":"14","author":"Bramlage","year":"2010","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib2","series-title":"Iron deficiency anaemia: assessment, prevention and control, a guide for programme managers","author":"WHO","year":"2001"},{"issue":"9","key":"10.1016\/j.atherosclerosissup.2012.10.012_bib3","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/mds.20102","article-title":"Impact of regular LDL apheresis on the development of restless legs syndrome","volume":"19","author":"Tings","year":"2004","journal-title":"Move Dis"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib4","unstructured":"Harrison's principles of internal medicine. 18th ed., p. 844\u201351."},{"issue":"9","key":"10.1016\/j.atherosclerosissup.2012.10.012_bib5","first-page":"A580","article-title":"Neue Parameter zur Diagnostik von Eisenmangelzust\u00e4nden, Retikulozytenh\u00e4moglobin und l\u00f6slicher Transferrinrezpetor","volume":"102","author":"Thomas","year":"2005","journal-title":"Deutsches \u00c4rzteblatt"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/ndt\/18.2.370","article-title":"Early prediction of response to intravenous iron supplementation by reticulocyte hemoglobin content and high-fluorescence reticulocyte count in hemodialysis patients","volume":"18","author":"Chuang","year":"2003","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ajh.1091","article-title":"Reticulocyte subpopulations and reticulocyte maturity index (RMI) rise as body iron status falls","volume":"67","author":"Choi","year":"2001","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1016\/j.atherosclerosissup.2012.10.012_bib8","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/asheducation-2010.1.338","article-title":"Clinical use of intravenous iron: administration, efficacy, and safety","volume":"2010","author":"Auerbach","year":"2010","journal-title":"Am Soc Hematol"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2012.10.012_bib10","first-page":"11","article-title":"The pharmacology and safety profile of ferric carboxymaltose (Ferinject\u00ae): structure\/reactivity relationships of iron preparations","volume":"23","author":"Geisser","year":"2009","journal-title":"Port J Nephrol Hypert"},{"issue":"6a","key":"10.1016\/j.atherosclerosissup.2012.10.012_bib11","first-page":"386","article-title":"Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications","volume":"60","author":"Bailie","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib12","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","article-title":"A comparative study of the physiochemical properties of iron isomaltoside 1000, a new intravenous iron preparation and its clinical implications","volume":"78","author":"Jahn","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1586\/14779072.6.5.629","article-title":"Comparison of different LDL apheresis methods","volume":"6","author":"Julius","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1526-0968.2002.00426.x","article-title":"First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management","volume":"6","author":"Schettler","year":"2002","journal-title":"Ther Apher"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib15","first-page":"22","article-title":"Characterization of iron availability from three different i.v. iron preparations in dialysis patients","volume":"8","author":"Macdougall","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/089686080802800205","article-title":"Intravenous iron: not just for hemodialysis patients anymore","volume":"28","author":"Wish","year":"2008","journal-title":"Peritoneal Dial Int"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib17","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1093\/ndt\/gfq260","article-title":"Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds","volume":"10","author":"Toblli","year":"2010","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib18","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patient with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study","volume":"18","author":"Coyne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2326-11-4","article-title":"Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data","volume":"11","author":"Moore","year":"2001","journal-title":"Blood Disord"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib20","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1046\/j.1523-1755.2002.00314.x","article-title":"Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran","volume":"61","author":"Michael","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib21","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/ndt\/gfh222","article-title":"Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety","volume":"19","author":"Michael","year":"2004","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib22","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1523-1755.2004.00872.x","article-title":"Iron sucrose in haemodialysis patients: safety of replacement and maintenance regimens","volume":"66","author":"Aronoff","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.atherosclerosissup.2012.10.012_bib23","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ajh.20056","article-title":"Parenteral iron therapy options","volume":"76","author":"Silverstein","year":"2004","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2012.10.012_bib24","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/j.ajkd.2008.05.033","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis","volume":"52","author":"Rozen-Zvi","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"5 Suppl. 3","key":"10.1016\/j.atherosclerosissup.2012.10.012_bib25","first-page":"S11","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","author":"National Kidney Foundation","year":"2006","journal-title":"Am J Kidney Dis"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T07:38:38Z","timestamp":1595317118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568812000232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1567568812000232"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2012.10.012","relation":{},"ISSN":["1567-5688"],"issn-type":[{"value":"1567-5688","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}